Yu Y, et al. Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2022;14:417–32.

PubMed  Google Scholar 

Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri VJEO. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022. https://doi.org/10.1016/j.esmoop.2022.100409.

Article  PubMed  PubMed Central  Google Scholar 

Deepak P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59: 101837.

Article  CAS  Google Scholar 

Gradishar WJ, et al. "NCCN Guidelines® insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484–93.

Article  PubMed  Google Scholar 

Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PJDDT. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today. 2022;27:2526.

Article  CAS  PubMed  Google Scholar 

P. Deepak et al., "c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity," p. 123160, 2023.

Murthy RK, et al. Tucatinib, Trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.

Article  CAS  PubMed  Google Scholar 

Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–29.

Article  CAS  PubMed  Google Scholar 

Koury J, et al. Immunotherapies: exploiting the immune system for cancer treatment. J Immunol Res. 2018;2018:9585614.

Article  PubMed  PubMed Central  Google Scholar 

Pandey P, et al. αvβ3 integrin and folate-targeted pH-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment. Bioengineering. 2024;11(8):800.

Article  PubMed  PubMed Central  Google Scholar 

Ferrario C, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-Masley C. Novel therapies for the treatment of HER2-positive advanced breast cancer: A Canadian perspective. Curr Oncol. 2022;29(4):2720–34.

Article  PubMed  PubMed Central  Google Scholar 

Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers. 2023;15(4):1320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med. 2011;366(2):109–19.

Article  PubMed  PubMed Central  Google Scholar 

Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.

Article  CAS  PubMed  Google Scholar 

Gámez-Chiachio M, Sarrió D, Moreno-Bueno GJC. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers. 2022;14(18):4543.

Article  PubMed  PubMed Central  Google Scholar 

Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

Article  CAS  PubMed  Google Scholar 

Nanda A, Pandey P, Rajinikanth P, Singh NJIJOBM. Revolution of nanotechnology in food packaging: Harnessing electrospun zein nanofibers for improved preservation-A review. Int J Biol Macromol. 2024. https://doi.org/10.1016/j.ijbiomac.2024.129416.

Article  PubMed  Google Scholar 

Miles D, et al. "Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245–55.

Article  CAS  PubMed  Google Scholar 

Tripathy D, et al. De Novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist. 2020;25(2):e214–22.

Article  CAS  PubMed  Google Scholar 

Wong Y, et al. Long-term survival of De Novo stage IV Human Epidermal Growth Receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313–8.

Article  CAS  PubMed  Google Scholar 

Battisti NML, Tong D, Ring A, Smith I. "Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401–8.

Article  CAS  PubMed  Google Scholar 

Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE. "Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24(6):751–7.

Article  CAS  PubMed  Google Scholar 

Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4(1):34.

Article  PubMed  PubMed Central  Google Scholar 

Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. "Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17(4):536–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.

Article  PubMed  Google Scholar 

Cardama GA, et al. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. Crit Rev Oncol/Hematol. 2018;124:29–36.

Article  CAS  PubMed  Google Scholar 

Lavudi K, Nuguri SM, Pandey P, Kokkanti RR, Wang Q-E. ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy. Life Sci. 2024. https://doi.org/10.1016/j.lfs.2024.123033.

Article  PubMed  Google Scholar 

Deepak P, et al. Pentapeptide cRGDfK-surface engineered nanostructured lipid carriers as an efficient tool for targeted delivery of tyrosine kinase inhibitor for battling hepatocellular carcinoma. Int J Nanomed. 2023;18:7021–46.

Article  CAS  Google Scholar 

Baselga J, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.

Article  CAS  PubMed  Google Scholar 

Loibl S, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27(8):1519–25.

Article  CAS  PubMed  PubMed Central